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Background: The glycoprotein MFG-E8 mediates phagocytic clearance of apoptotic cells and influences the
pathogenesis and progression of inflammatory diseases. MFG-E8 was shown to attenuate the progression of
inflammation and to improve survival in septic rats. Accumulating evidence suggests an immunomodulatory link
between MFG-E8 and the pro-inflammatory chemokine fractalkine, which may determine the severity of pain,
fibrosis, and inflammation in chronic pancreatitis (CP).
Methods: The expression and localization of MFG-E8 was investigated in CP (n = 62), and normal pancreas
(NP; n = 34) by QRT-PCR, Western-blot and immunohistochemistry analyses. Results were correlated with mRNA
expression of fractalkine, CX3CR1, and with the presence and degree of pain and fibrosis. Human pancreatic stellate
cells (hPSCs) were isolated from CP tissues and evaluated for MFG-E8 mRNA expression after fractalkine stimulation.
Results: MFG-E8-mRNA was significantly overexpressed in CP and isolated hPSCs when compared to NP.
Western-blot and immunohistochemistry analysis confirmed accumulation of MFG-E8 in CP, with noticeably
increased MFG-E8 immunoreactivity in tubular complexes. MFG-E8 expression correlated significantly with
fractalkine expression, severe fibrosis, and the presence of pain in CP patients. Stimulation of hPSCs with fractalkine
led to a significant increase in MFG-E8 expression.
Conclusions: In the present study, we demonstrated for the first time that MFG-E8 is significantly up-regulated in
CP patients and together with fractalkine correlated noticeably with severe fibrosis and the presence of pain. hPSCs
overexpress MFG-E8 upon fractalkine stimulation in vitro, which underlines the suggested immunmodulatory link in
CP and may be a key mechanism in CP fibrogenesis and pain generation. Taken together, these novel findings
suggest that MFG-E8 blockade may be a promising tool for future immunotherapy in CP to attenuate both fibrosis
and pain sensation.
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Chronic pancreatitis (CP) is a chronic inflammatory dis-
ease, characterized by a progressive destruction of the
pancreatic parenchyma, which often results in severe
exocrine and endocrine insufficiency [1,2]. Furthermore,
CP is characterized by an impressive infiltration of vari-
ous subsets of inflammatory cells and severe fibrosis* Correspondence: gueralp.ceyhan@tum.de
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reproduction in any medium, provided the orwith distinct accumulation of extracellular matrix. In-
flammatory cell infiltration in CP is especially striking in
intrapancreatic nerves and has been suggested to lead to
the neuropathic pain syndrome in CP patients [3]. More-
over, it has been repeatedly shown that inflammatory cells
can influence fibrogenesis by supporting the activation
of human pancreatic stellate cells (hPSCs), which conse-
quently release ECM proteins leading to fibrosis [4,5]. This
activation of hPSCs is driven by the release of cytokines
like PDGF, TNFα, and TGFβ from mononuclear cells and
leads to a more pro-fibrogenic and pro-inflammatory cell
like phenotype of hPSCs. Following activation, hPSCs
secrete autocrine factors like periostin and TGFβ whichl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cycle of inflammation, fibrosis, and pain in chronic pan-
creatitis [6].
Milk fat globule epidermal growth factor 8 (MFG-E8) is
a glycoprotein which has originally been discovered in
milk-fat globules of lactating mice [7]. MFG-E8 contains
one epidermal growth factor (EGF)-like domain with an
Arg-Gly-Asp (RGD) motif and two tandem c domains
(C1 and C2) with homology to discoidin-type lectins and
two membrane-binding domains of blood-clotting factors
V and VIII [8,9]. MFG-E8 has a signal sequence at the
amino-terminus, but no putative hydrophobic membrane-
spinning region, suggesting that it is a secreted protein. It
binds to cells via its RGD motif, particularly strongly
to cells expressing the integrins αvβ3 and αvβ5 [10-12].
MFG-E8 specifically binds to phosphatidylserine exposed
on plasma membranes of apoptotic cells and works as a
bridging molecule between apoptotic cells and phagocytes,
tagging them for directed elimination [13,14].
The localization of MFG-E8 is not limited to inflamma-
tory cells, since it is ubiquitously expressed in different cells
and tissue types [15]. It is released by apoptotic endothelial
cells which can trigger macrophage reprogramming into
an anti-inflammatory phenotype [16]. MFG-E8 has been
shown to directly activate proliferation in aortic vascular
smooth muscle cells via phosphorylation of ERK1/2 [17]. A
recent study by Aziz et al. showed that MFG-E8 attenuates
neutrophil infiltration in acute lung injury [18], meaning
that MFG-E8 may be able to directly influence the quality
of inflammatory cell infiltrations. Moreover, it has been
shown that microglia, the phagocytes of the brain, upregu-
late MFG-E8 upon fractalkine stimulation to label the
apoptotic neurons and thereby help them recognize their
target cells. Here, again, seems that MFG-E8 works as a
bridging molecule between apoptotic cells/neurons and
microglia [19]. As in the nervous system, MFG-E8 expres-
sion can be induced in peritoneal macrophages of septic
rats and mice by the chemokine fractalkine. Elevated frac-
talkine levels lead to higher MFG-E8 expression and
enhanced clearance of apoptotic cells, suggesting a possible
novel treatment for patients in sepsis [20]. In this context,
we recently demonstrated that pancreatic overexpression of
fractalkine in CP is closely linked to visceral pain and to the
recruitment of inflammatory cells into the pancreatic tissue
and especially to intrapancreatic nerves, with subsequent
generation of pancreatic neuritis [21].
By mediating the clearance of apoptotic cells, MFG-E8
attenuates the progression of inflammation and improves
survival in septic rats [22,23]. In murine experimental
acute colitis, MFG-E8 was down-regulated in the acute
phase of colon inflammation, while it gradually became
up-regulated during the healing phase [24,25].
Up to now, the potential role and expression of MFG-
E8 has never been investigated in CP, especially in regardto possible interactions with the chemokine fractalkine,
inflammatory cell infiltration, fibrosis and pain. For this,
the expression and localization of MFG-E8 was analyzed
in normal pancreas, CP, and in freshly isolated hPSCs




A total of 62 CP tissue samples were collected from
patients undergoing pancreatic head resection (44 males,
18 females, median age 45 years). The etiology of the
pancreatitis was alcoholic CP (n = 30), biliary CP (n = 3),
idiopathic CP (n = 29). Diabetes was present in 15 of
these 62 patients. All patients were informed verbally,
and written informed consent was obtained. Normal
pancreatic tissue samples were obtained from healthy
organ donors (n = 34; 21 male, 13 female; median age
38 years) whenever there was no suitable recipient avail-
able. The study protocols were approved by the Ethics
Committees of the University of Bern (Switzerland) and
the University of Heidelberg (Germany).
The types of surgical resection performed were clas-
sical Whipple’s procedure in 7 cases, pylorus-preserving
Whipple’s procedure in 8 cases, pancreatic left resection in
4 cases, duodenum-preserving pancreatic head resection
(Beger’s procedure) in 24 cases, a duodenum-preserving
pancreatic head resection (Bern modification) in 36 cases.
Resected pancreatic tissues were divided into several
parts and the aliquots were (a) frozen in liquid nitrogen
and stored at −80°C for protein extraction, (b) taken into
RNA-later (Ambion, Huntington, UK) for RNA extrac-
tion, and (c) fixed in 5% paraformaldehyde and later em-
bedded in paraffin for immunohistochemical analysis.
In all CP patients, the individual pain score was re-
gistered before operation, including pain intensity and
frequency as described earlier [21,26,27]. The following
scale was used to grade the individual intensity of pain:
0 = none, 1 =mild, 2 =moderate and 3 = strong pain. The
frequency of pain was graded as 1 =monthly, 2 = weekly
and 3 = daily. Pain severity was then calculated by multi-
plying pain intensity and frequency. According to this pain
score, the patients were finally divided into three groups,
as described earlier [21,26,27] Pain 0 (0), representing the
group of patients who did not have any pain; Pain I (1–3),
representing the group of patients with mild pain; and
Pain II (4–9), the group of patients who suffered from
moderate to severe pain [21,26,27].
Reagents
Reagents purchased were as follows: DMEM, Trypsin-
EDTA, and penicillin-streptomycin from Invitrogen
(Karlsruhe, Germany); fetal bovine serum (FBS) from
PAN Biotech. For both immunohistochemical and western
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Santa Cruz Biotechnology (Heidelberg, Germany) was
used. For western blot analysis, anti-mouse IgG HRPO-
linked antibody and ECL immunoblotting detection
reagents were purchased from Amersham Biosciences
(Amersham, UK). DAKO Envision system (Hamburg,
Germany) was used for immunohistochemistry. All other
reagents were from Sigma-Aldrich Chemical Company
(Taufkirchen, Germany).
Immunohistochemistry
Consecutive 3 μm paraffin-embedded tissue sections of
both groups were analysed for MFG-E8 immuno-
staining using the DAKO Envision system (DAKO,
Hamburg, Germany), as described previously [26].
Mouse monoclonal MFG-E8 antibody (1:800, Santa
Cruz, Heidelberg, Germany) was diluted in DAKO anti-
body dilutant (DAKO, Hamburg, Germany). Mouse
IgG (DAKO, Hamburg, Germany) was used as negative
control. Digital imaging was performed with the Zeiss
AxioCam HR system (Carl Zeiss AG, Oberkochen,
Germany).
Western blot analysis
Protein extraction and western blot analysis of pancre-
atic tissues were performed as described previously [26].
A monoclonal mouse MFG-E8 antibody (Santa Cruz,
Heidelberg, Germany) was used at the dilution 1:1000 at
4°C overnight. Antibody detection was performed with
an enhanced chemiluminescence reaction (Amersham,
UK). Equal loading was assured by stripping the blots
and probing with the mouse monoclonal anti-GAPDH
antibody (Santa Cruz, Heidelberg, Germany). After
digital scanning of the western blot films, densitomet-
ric analysis was carried out using the open source
ImageJ software provided by the National Institutes of
Health. Specific signal intensity was calculated and
was corrected for the matching equal loading densities
as described previously [21].
Clinicopathological analysis
Consecutive sections obtained from the pancreatic tissue
of each patient were stained with hematoxylin and eosin
for histomorphological examination. Histopathological
analysis was carried out by two independent observers
(JGD, IED) blinded to QRT-PCR data, followed by reso-
lution of any differences by joint review and consultation
with a third observer (FB). Histomorphological evaluation
of the specimens included the severity of fibrosis, which
was graded according to a scoring system as described
earlier [21]. The severity of fibrosis was revealed by the
addition of intralobular and perilobular fibrosis scores as
mild 0 (0–4), moderate I (5–9) or severe II (10–12)fibrosis [21]. No pathomorphological abnormalities were
detected within the group of normal pancreas.
Real-time light cyclerW quantitative polymerase chain
reaction (QRT-PCR)
All reagents and equipment for mRNA/cDNA preparation
were purchased from Roche Applied Science (Mannheim,
Germany). Extraction of mRNA from normal and CP
tissues was prepared by automated isolation using the
MagNa Pure LC instrument and isolation kits I (for cells)
and II (for tissue). cDNA was prepared using the 1st strand
cDNA synthesis kit for RT-PCR according to the manufac-
turer’s instructions. Quantitative real-time PCR was per-
formed with the Light Cycler Fast Start DNA SYBR Green
kit. All primers were obtained from Search-LC (Heidelberg,
Germany). The calculated number of specific transcripts
were normalized to the housekeeping genes cyclophilin B
(CPB) and hypoxanthine guanine phosphoribosyltransferase
(HPRT), and expressed as the amount per μl of input
cDNA, as described previously [28].
Isolation and cell culture of human pancreatic stellate
cells
Human pancreatic stellate cells (hPSCs) were isolated
from freshly resected pancreatic tissue of patients with
chronic pancreatitis using the outgrowth method described
by Bachem et al. [5]. hPSCs were cultivated in a 1:1 dilu-
tion of Ham’s F-12 nutrient medium and low glucose
Dulbecco’s modified Eagle’s medium (DMEM) supplemen-
ted with penicillin, streptomycin, amphotericin and 10%
FBS. To verify the purity of the hPSCs preparation, western
blot analysis with primary mouse monoclonal antibody
α-SMA (1:100; DAKO Cytomation Hamburg, Germany)
was performed.
Fractalkine stimulation of hPSCs
The isolated hPSCs were grown in six-well plates for
RNA extraction. Fresh medium was supplemented with
1% of FBS containing fractalkine (10 and 100 ng/ml)
for functional experiments as soon as the cells reached
70% confluence. PBS was used as a control. Changes in
MFG-E8 mRNA expression in hPSCs were analyzed in
cell lysates after 12, 24 and 48 h using QRT-PCR. All
experiments were repeated three times.
Statistical analysis
Results are expressed as mean ± standard error of the
mean (SEM). To compare more than two subgroups of
samples with respect to MFG-E8 mRNA levels in tissue
samples, the Kruskal-Wallis test was used. When a
significant result was found, further pair-wise compari-
sons of the subgroups were performed by using the
Dunn’s post test. The relationship between MFG-E8,
fractalkine, CX3CR1, and the degree of fibrosis and pain
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correlation coefficient r and the corresponding p-value.
Two-sided p-values were always computed, and an effect
was considered statistically significant at a p-value ≤ 0.05.
Results
MFG-E8 expression in pancreatic tissues
Initially, quantitative RT-PCR analysis was performed to
investigate MFG-E8-mRNA expression in normal pancre-
atic tissue and in chronic pancreatitis. In normal pancreas,
the expression of MFG-E8 was 345 ± 37 transcripts/μl,
which was significantly increased to 762 ± 97 transcripts/
μl (p < 0.04) in chronic pancreatitis (Figure 1A). Western
blot analysis confirmed the accumulation of MFG-E8 in
chronic pancreatitis. MFG-E8 protein levels showed a
more than 2-fold increase in chronic pancreatitis com-
pared with normal pancreatic tissues (Figure 1B). MFG-E8
expression did not significantly differ between diabetic or
non-diabetic patients (p = 0.32) or in between different
etiologies (p = 0.15).
Immunolocalization of MFG-E8 in normal pancreas and
chronic pancreatitis
To determine the localization of MFG-E8 in the normal
pancreas and in chronic pancreatitis, immunohistochem-
ical analysis was performed. In normal pancreatic tissue
samples, moderate MFG-E8 immunoreactivity was exclu-
sively evident in ductal and centroacinar cells (Figure 2),
whereas vessels, intrapancreatic nerves, and islets did
not show any MFG-E8 immunoreactivity (Figure 2). In
chronic pancreatitis, MFG-E8 showed increased immu-
noreactivity in tubular complexes (Figure 2). Interestingly,
the extracellular matrix (ECM) itself did not show any
immunoreactivity for MFG-E8. However, MFG-E8 im-
munoreactivity, especially around tubular complexes, was
noticeably increased in pancreatic areas neighboring tissue
sections with increased fibrosis and ECM (Figure 2C
and D).A MFG-E8 in NP vs. CP





















Figure 1 MFG-E8 in pancreatic tissues. MFG-E8-mRNA expression, analyz
compared to chronic pancreatitis patients (n = 62) (A). Western blot analysiCorrelation of MFG-E8 with fractalkine and CX3CR1
To identify possible mediators of MFG-E8, the mRNA
expression of fractalkine and CX3CR1 was analyzed by
QRT-PCR in all chronic pancreatitis tissue samples and
correlated with MFG-E8 mRNA expression. The MFG-E8
mRNA expression correlated positively with fractalkine
expression (p < 0.03, r-value: 0.33), whereas correlation
with its receptor CX3CR1 failed to reach statistical signifi-
cance (Figure 3A + B).
MFG-E8 and pancreatic pain
Out of the 62 investigated patients, 10 patients had
no pain (Pain 0), 11 patients had mild pain (Pain I) and
41 patients had moderate to severe pain (Pain II). Inter-
estingly, patients with no pain showed significantly lower
MFG-E8 mRNA levels (206 ± 46 transcripts/μl) than
patients with mild (896 ± 263 transcripts/μl; p < 0.05)
or moderate to severe pain (841 ± 130 transcripts/μl;
p < 0.01; Figure 4).
The potential impact of MFG-E8 on pancreatic fibrosis in
chronic pancreatitis
To investigate the potential impact of MFG-E8 on pancre-
atic fibrosis, the severity of fibrosis was determined in
every patient and correlated to the MFG-E8 mRNA ex-
pression within the CP tissue. MFG-E8 mRNA expression
was found to be positively associated with the severity of
fibrosis in CP. MFG-E8 expression showed a significant
(p < 0.01) increase in the severe fibrosis group II (1046 ±
175 transcripts/μl) compared with the mild fibrosis group
I (472 ± 107 transcripts/μl; Figure 5A). To detect the influ-
ence of MFG-E8 on fibrogenesis in CP, hPSCs were freshly
isolated from human CP resection specimens. Untreated
hPSCs from CP tissue showed almost 6 times higher
levels of MFG-E8 mRNA (4388 ± 541 transcripts/μl)
than the average expression in CP tissue lysates (761 ±
95 transcripts/μl; Figure 5B). In order to assess the pu-





















ed by QRT-PCR in pancreatic tissues of healthy organ donors (n = 34),
s of MFG-E8 protein levels in pancreatic tissue from CP patients (B).
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FDB
normal pancreas chronic pancreatitis
A
Figure 2 Immunoreactivity of MFG-E8 in normal pancreas (A + B) and chronic pancreatitis (C - F). In normal pancreatic tissue samples,
immunostaining of MFG-E8 was only moderately present in the ducal and centroacinar cells (A + B). In chronic pancreatitis, MFG-E8 showed
increased immunoreactivity in tubular complexes (C - F).
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concentrations of recombinant fractalkine. After 12 and
24 hours of fractalkine stimulation QRT-PCR analysis
revealed an increasing effect on MFG-E8 expression in
hPSCs, but failed to reach a statistical significance (data
not shown). However, this increase in MFG-E8 mRNA ex-
pression in fractalkine stimulated hPSCs became statisti-
cally significant after 48 hours stimulation with 100 ng/ml
fractalkine when compared to the control group (7193 ±
1186 transcripts/μl vs. 4388 ± 765 transcripts/μl, p < 0.01;
Figure 5C).
Discussion
MFG-E8 was first identified in the process of phagocytic
clearance of apoptotic cells [13]. More recently, it has been
shown that MFG-E8 deficient mice show severe inflam-
matory imbalances, and an MFG-E8-mediated potential
therapeutic benefit is evident in experimental inflammatory
conditions [18,20,22-25,29-32]. Previous studies have eluci-
dated the role of MFG-E8 in diverse neoplastic and acute
inflammatory diseases, yet this is the first study to investi-
gate MFG-E8 expression in chronic pancreatitis.
In the present study, we demonstrated for the first time
that MFG-E8 is significantly up-regulated in patients with
chronic pancreatitis. Interestingly, and in contrast to acute
inflammatory diseases where MFG-E8 is under-expressed
in the acute phase and recombinant MFG-E8 seems benefi-
cial, MFG-E8 expression in chronic pancreatitis is signifi-
cantly higher than in normal pancreatic tissue. Our analysis
further revealed that this overexpression is directly related
to the presence of pain and associated with severe fibrosis
in these patients. The connective link between the chemo-kine fractalkine and MFG-E8 that became evident in
chronic pancreatitis further underlines the potential of
MFG-E8 as a future therapeutic target in the treatment of
painful chronic pancreatitis.
Long-lasting pancreatic pain is the most prominent
symptom of chronic pancreatitis which has recently been
suggested to be a mixed-type pain from both nociceptive
and neuropathic mechanisms [33]. Previous studies have
demonstrated a key correlation between the extent of
neural damage, neural plasticity, neural inflammatory cell
infiltration (pancreatic neuritis), and the pain frequency
and intensity of CP patients, thereby underlining the im-
portance of neuropathic mechanisms in CP pain gener-
ation [27,34]. In this study we were able to demonstrate
that MFG-E8 correlates significantly with the presence of
pancreatic pain in CP patients. This observed correlation
may theoretically be explained by three different possible
pathways: a) MFG-E8 expression may be induced by a yet
unknown common factor that likewise induces pain in CP
patients, b) MFG-E8 may have an analgesic potential and
is therefore released by CP tissue as a reaction on a pain
stimulus in the attempt to limit pain sensation. While
these possibilities can currently not be completely ruled
out, it seems more likely that c) MFG-E8 may influence
the extent of neural alterations in chronic pancreatitis and
thereby aggravate chronic pain sensation in these patients.
While the exact mechanisms remain to be unravelled, a
direct negative influence of MFG-E8 on neural inflamma-
tory cell infiltration seems unlikely since MFG-E8 has
been shown to rather attenuate neutrophil infiltration in
acute lung injury [18]. It is more likely that MFG-E8 mod-
ulates pain sensations by directly aggravating the extent of
MFG-E8 & Fractalkine in CP
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Figure 3 Correlation of MFG-E8 mRNA expression with
fractalkine mRNA expression (P < 0.03) (A), and CX3CR1 mRNA
expression (B).
























Figure 4 Relationship of MFG-E8 mRNA expression with the
presence/severity of pain in patients with chronic pancreatitis.
Data are expressed as mean ± standard error of the mean (SEM).
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osis of viable neurons and/or glial cells as it has very
recently been shown for states of neuroinflammation [35].
Accordingly, and consistent with findings in cancer ther-
apy, MFG-E8 blockade - not treatment with recombinant
MFG-E8 - may be a possible treatment for chronic pan-
creatic pain. This idea seems especially tempting since
MFG-E8, as a secreted protein, may be rather easily tar-
geted by appropriate blocking antibodies.
Our understanding of the cellular and molecular events
leading to the development of pancreatic fibrosis has
improved significantly in recent years, largely due to the
isolation and characterization of pancreatic stellate cells
(PSCs) which play a key role in fibrogenesis [5,36]. Stellate
cells are resident cells of the pancreas, located at the baso-
lateral aspect of acinar cells. During inflammatory injury,
PSC become activated by migrating mononuclear inflam-
matory cells to produce and secrete extracellular matrix
proteins such as collagen, fibronectin, and laminin, but alsopro-inflammatory cytokines and chemokines [37-40]. Our
data show that MFG-E8 is highly expressed in human
pancreatic stellate cells isolated from chronic pancreatitis
tissue, suggesting that MFG-E8 is secreted in high levels by
activated hPSC in the chronic state of pancreatitis. On the
other hand, high MFG-E8 expression may be in indicator
for enhanced hPSC turnover in chronic pancreatitis with a
higher rate of phagocytosis of dying hPSCs. This is further
underlined by our immunohistological findings that MFG-
E8 immunoreactivity was noticeably increased in pancre-
atic areas neighboring tissue sections with increased fibro-
sis and ECM. While the ECM itself showed little to no
immunoreactivity for MFG-E8 in our study, neighboring
regions which are known to contain the activated pancre-
atic stellate cells showed the highest immunoreactivity [6].
Furthermore, we were able to show that MFG-E8 expres-
sion significantly correlated with severe fibrosis in CP
patients. According to our observed correlations with pain
this correlation as such may be explained by different pos-
sible mechanisms. The most likely however is that MFG-
E8 may aggravate fibrogenesis in CP patients, possibly by
direct modulation of hPSC activation. This MFG-E8 over-
expression in hPSC may be on the one hand an indicator
of apoptosis, but on the other hand indicate enhanced
growth signaling, as MFG-E8 was previously shown to
induce PDGF signaling and regulate cyclin D1/D3 expres-
sion, especially in neoplastic cells. However, since smoking
habits were unfortunately not recorded systematically in
the medical history reports we cannot entirely exclude
smoking as a systemic confounder influencing MFG-E8
expression in CP.
Another important finding of our study is the strong
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Figure 5 Relationship of MFG-E mRNA expression with the presence/degree of fibrosis in CP (A). Comparison of MFG-E8 mRNA
expression of human pancreatic stellate cells, isolated from pancreatic tissue of patients with chronic pancreatitis compared to CP tissue as such
(B). Comparison of MFG-E8 expression in hPSCs 48 hours after stimulation with 10 ng/ml and 100 ng/ml fractalkine compared to unstimulated
hPSCs (C). Data are expressed as mean ± standard error of the mean (SEM).
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the fourth class of chemokines and is known to mediate
both chemotaxis and adhesion [41]. Fractalkine can be
released by proteolysis at a membrane-proximal region
by TNF-α converting enzyme (TACE, ADAM17) and
ADAM10 [42,43]. It was furthermore reported to be
involved in the pathogenesis and progression of numer-
ous inflammatory diseases including chronic pancreatitis
[21,44-48]. Recent investigations by our group revealed
that the expression of fractalkine strongly correlates with
the degree of fibrosis, the severity of neural inflamma-
tory cell infiltration (“pancreatic neuritis”), and the se-
verity and frequency of pain in chronic pancreatitis [21].
The correlation of MFG-E8 expression with fractalkine
may therefore suggest an equally important role of
MFG-E8 in chronic pancreatitis. This assumption is
underlined by the fact that MFG-E8 was likewise signifi-
cantly correlated to the presence of pain and severe fibro-
sis in chronic pancreatitis. At last, fractalkine expression
seems to be closely linked to MFG-E8 expression since
fractalkine stimulation of peritoneal macrophages andmicroglia has been reported to lead to MFG-E8 overex-
pression [19,20]. Likewise, we were able to show for the
first time that isolated human pancreatic stellate cells
express MFG-E8 and show a significant increase in MFG-
E8 expression after fractalkine stimulation. We therefore
could illustrate that the connective link between MFG-E8
and fractalkine, which has been shown for microglia and
macrophages in acute inflammatory conditions is similarly
evident in hPSC in chronic pancreatitis. This connective
link again underlines the significance of MFG-E8 as a
potential therapeutic target.
Conclusion
In conclusion, our novel findings demonstrate that
MFG-E8 is overexpressed in chronic pancreatitis and
that MFG-E8 expression is closely linked to expression
of the chemokine fractalkine. Isolated hPSCs, which are
thought to play a key role in fibrogenesis, showed especially
high expression of MFG-E8 and even further increased
their MFG-E8 expression upon fractalkine stimulation.
MFG-E8 expression is moreover strongly associated with
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promising candidate for future investigations in regards to
its potential as a novel therapeutic target in future treat-
ment of painful chronic pancreatitis.
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